C07K 7/06(20130101), A61K 38/00(20130101)
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
Hazlehurst, Lori; McLaughlin, Mark; Jain, Priyesh; and Dalton, William S., "Integrin interaction inhibitors for the treatment of cancer" (2014). USF Patents. 160.
H. Lee Moffitt Cancer Center and Research Institute, Inc. University of South Florida